News & Updates
Stay updated with the latest announcements, research findings, and milestones from Adinova as we continue to innovate in medical technology.
Peer Review Publications
Mesenteric fat cryolipolysis attenuates insulin resistance in the Ossabaw swine model of the metabolic syndrome. Surg Obes Relat Dis. 2023 Apr;19(4):374-383.
Grants
SBIR Phase I: "Mesenteric Fat Cryolipolysis to Reverse Insulin Resistance". 2023. Awarding agency: NIDDK
SBIR Phase II: selected for funding 2026
Clinical Experience
Adinova Medical is currently sponsoring a first-in-human clinical trial to assess mesenteric cryolipolysis in type 2 diabetes patients with visceral obesity. Thus far, significant visceral fat reduction was recorded after 3 months and was durable at 1 year follow-up. The reduction in visceral fat was accompanied by improvement in metabolic health.